MarketGrader

Jeremy Grantham on the Market's Outlook

Future earnings growth must start with revnues. Revenues are still declining with earnings growth coming from cost cutting. The problem with p/e valuations is that the denominator keeps dropping so we never get to the historical low p/e marking a MKT bottom. Ditto dividends. Quality of earnings becomes even more important now. Look for companies adding economic value. Those with high MG grades are doing so, but the grades are based on the previous reporting periods.

Campbell's Is a S(o)uper Buy - Barron's

$CPB has been around 44 or a sell since Nov '08 On Marketgraer.Com. The stock fell coincidentally with our down grade tomhold in Oct. Low payout ratio good yield in todays environment, trying to catch its 50 MA. Agree it's a tempting by in anticipation of low/modest earnings growth

Same-Store Sales: Drugstores, Supermarkets, Fast Food Weathering Recession

$SVU has been a sell since Dec 2007 and even now is a sell with a MarketGRader.Com score of 22. Industry analysis is negative

Same-Store Sales: Drugstores, Supermarkets, Fast Food Weathering Recession

Both $wag and $cvs have Marketgrader.Com weak buy scores of 62 with WAG going from sell to buy in early April. Industry top down analysis is positive

Johnson & Johnson: A Solid Dividend Aristocrat

Agree, Although with a score of 63+ on MarketGrader.Com it is a weak buy, but the Profitability and Cash Flow are A & A- respectively assures us of good dividend coverage history. See our report on the URL tinyurl.com/c55t53



On Apr 27 11:40 AM dividendgrowthinvestor wrote:

> Writeup on JNJ is EXCELLENT and as a person who has achieved financial
> independence through dividends this recommendation is GREAT

Abbott Laboratories: Dividend Stock Analysis

$ABT is certainly a safe Dividend payor. In MarketGrader.
Com the Cash Flow is ranked A-. Look at our report here as published online by Barron's tinyurl.com/darpy7